

The background of the entire page is a nighttime photograph of the Mole in Turin, Italy. The dome is illuminated with a bright white light, making it stand out against the dark blue night sky. The surrounding city lights are visible in the background, and a bright light source in the lower right corner creates a lens flare effect.

1st European Myeloma Network Meeting

Turin
April 19-21, 2018

Lingotto Conference Center

PROGRAM

UNDER THE AUSPICES OF:

CITTÀ DI TORINO

REGIONE PIEMONTE

UNIVERSITÀ DI TORINO

AZIENDA OSPEDALIERO-UNIVERSITARIA

Città della Salute e della Scienza di Torino – Presidio Ospedaliero Le Molinette

SIE – Società Italiana di Ematologia

SIES – Società Italiana di Ematologia Sperimentale

GITMO - Gruppo Italiano per il Trapianto di Midollo Osseo,
cellule staminali emopoietiche e terapia cellulare

AIL - Associazione Italiana contro le Leucemie-linfomi e mieloma Onlus

GIMEMA - Gruppo Italiano Malattie Ematologiche dell'Adulto

IPASVI - Federazione Nazionale Collegi Infermieri Professionali,
Assistenti sanitari, Vigilatrici d'Infanzia

WELCOME MESSAGE

Dear Colleagues and Friends,

It is my great pleasure and honor to invite you to attend the 1st EMN 2018 meeting taking place this year, from April 19 - 21, 2018, in Turin, Italy.

This event is organized under the umbrella of the European Myeloma Network and it seeks to go beyond national boundaries by including research groups from all over Europe.

The location of the meeting is Lingotto Conference Center, an ideal venue to host important international congresses and big events. At the foot of the Alps, Turin is a majestic city, the former capital of Italy, easily reachable and well connected to the rest of Europe. Here you will enjoy both the meeting and this fascinating city.

I am sure the EMN2018 will be a great opportunity for everyone to strengthen bonds between teams and start new collaborations, which will ultimately result in new opportunities and advances for the benefit of patients.

I am very much looking forward to welcoming you soon.



Mario Boccardo – Turin
On behalf of the EMN2018 Board

SCIENTIFIC BOARD

Mario Boccardo (Italy)
Hermann Einsele (Germany)
Maria-Victoria Mateos (Spain)
Philippe Moreau (France)
Pieter Sonneveld (The Netherlands)

SCIENTIFIC SECRETARIAT

Francesca Gay (Italy)
Niels van de Donk (The Netherlands)

FACULTY

Michel	Attal	Toulouse, France	Heinz	Ludwig	Vienna, Austria
Hervé	Avet-Loiseau	Toulouse, France	Fabio	Malavasi	Turin, Italy
Annalisa	Bernardini	Turin, Italy	Maria-Victoria	Mateos	Salamanca, Spain
Juan	Bladé	Barcelona, Spain	Philip L.	McCarthy	Buffalo, USA
Mario	Boccardo	Turin, Italy	Giampaolo	Merlini	Pavia, Italy
Felice N.	Bombaci	Turin, Italy	Monique	Minnema	Utrecht, The Netherlands
Patricia W.C.	Bosman	Amsterdam, The Netherlands	Mohamad	Mohty	Paris, France
Sara	Bringhen	Turin, Italy	Vittorio	Montefusco	Milan, Italy
Michele	Cavo	Bologna, Italy	Philippe	Moreau	Nantes, France
Gordon	Cook	Leeds, United Kingdom	Gareth J.	Morgan	Little Rock, USA
Michel	Delforge	Leuven, Belgium	Kate	Morgan	Brussels, Belgium
Meletios A.	Dimopoulos	Athens, Greece	Nikhil C.	Munshi	Boston, USA
Christoph	Driessen	St. Gallen, Switzerland	Pellegrino	Musto	Rionero in Vulture, Italy
Brian G.M.	Durie	Los Angeles, USA	Inger S.	Nijhof	Amsterdam, The Netherlands
Hermann	Einsele	Würzburg, Germany	Enrique M.	Ocio	Salamanca, Spain
Monika	Engelhardt	Freiburg, Germany	Massimo	Offidani	Ancona, Italy
Francesca	Gay	Turin, Italy	Albert	Oriol	Barcelona, Spain
Nicola	Giuliani	Parma, Italy	Roger	Owen	Leeds, United Kingdom
Hartmut	Goldschmidt	Heidelberg, Germany	Giovanni	Palladini	Pavia, Italy
Roman	Hájek	Ostrava, Czech Republic	Maria Teresa	Petrucci	Rome, Italy
Jean-Luc	Harousseau	Nantes, France	Torben	Plesner	Vejle, Denmark
Jens	Hillengass	Buffalo, USA	Marc S.	Raab	Heidelberg, Germany
Davine	Hofste op Bruinink	Boston, USA	Paula	Rodriguez Otero	Navarra, Spain
Graham	Jackson	Newcastle upon Tyne, United Kingdom	Laura	Rosiñol	Barcelona, Spain
Hans E.	Johnsen	Aalborg, Denmark	Pieter	Sonneveld	Rotterdam, The Netherlands
Martin F.	Kaiser	London, United Kingdom	Christian	Straka	Berg, Germany
Efstathios	Kastritis	Athens, Greece	Evangelos	Terpos	Athens, Greece
Marie José	Kersten	Amsterdam, The Netherlands	Steven P.	Treon	Boston, USA
Sigurdur	Kristinsson	Reykjavík, Iceland	Rossella	Troia	Turin, Italy
Robert A.	Kyle	Rochester, USA	Niels	van de Donk	Amsterdam, The Netherlands
Alessandra	Larocca	Turin, Italy	Anders	Waage	Trondheim, Norway
Xavier	Leleu	Poitiers, France	Elena	Zamagni	Bologna, Italy
Sarah J.	Lonergan	Rotterdam, The Netherlands	Renato	Zambello	Padova, Italy
Sagar	Lonial	Atlanta, USA	Sonja	Zweegman	Amsterdam, The Netherlands

TIMETABLE

Thursday, April 19, 2018	Friday, April 20, 2018	Saturday, April 21, 2018
	8.00 - 9.00 MEET THE EXPERTS	8.00 - 9.00 MEET THE EXPERTS
11.30 - 11.40 OPENING CEREMONY	9.00 - 10.15 TREATMENT STRATEGY IN MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS	9.00 - 10.15 TREATMENT STRATEGY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: NOVEL THERAPIES, WHEN AND IN WHICH PATIENTS?
11.40 - 11.55 OPENING LECTURE	10.15 - 11.10 RECOMMENDATIONS AND CHALLENGES: OF THE MANY TREATMENT OPTIONS	10.15 - 10.55 BEST ABSTRACTS II - ORAL PRESENTATIONS
11.55 - 12.45 MGUS AND SMM: RECOMMENDATIONS AND CHALLENGES	11.10 - 11.30 COFFEE BREAK and POSTER VIEWING	10.55 - 11.30 COFFEE BREAK and POSTER VIEWING
12.45 - 13.45 LUNCH and POSTER VIEWING	11.30 - 13.00 JANSSEN SPONSORED SYMPOSIUM Multiple myeloma: what are your goals for treating patients in 2018?	11.30 - 12.50 RECOMMENDATIONS AND CHALLENGES: HOW TO MAKE SENSE OF THE MANY TREATMENT OPTIONS AVAILABLE AT RELAPSE
13.45 - 15.15 CELGENE SPONSORED SYMPOSIUM IMiD® compound-based treatments for multiple myeloma	13.00 - 13.30 PATIENT PERSPECTIVE: PATIENT	12.50 - 13.30 SIDE EFFECTS MANAGEMENT
15.15 - 16.00 MULTIPLE MYELOMA BIOLOGY AND GENOMICS	13.30 - 14.30 LUNCH and POSTER VIEWING	13.30 - 13.40 CONCLUSIONS AND FINAL GREETINGS
16.00 - 16.30 COFFEE BREAK and POSTER VIEWING	14.30 - 16.00 PRIME ONCOLOGY SPONSORED SYMPOSIUM Treatment decisions for relapsed/refractory multiple myeloma: Fitting the pieces together	
16.30 - 18.00 AMGEN SPONSORED SYMPOSIUM Multiple myeloma - Treatment strategies in a radically changing therapy landscape	16.00 - 16.50 SPECIAL CONDITIONS - WALDENSTRÖM	
18.00 - 19.00 MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA	16.50 - 17.20 COFFEE BREAK and POSTER VIEWING	
19.00 - 19.40 AGGRESSIVE DISEASE - EXTRAMEDULLARY DISEASE/PLASMA CELL LEUKEMIA	17.20 - 18.10 SPECIAL CONDITIONS - AL AMYLOIDOSIS	
19.40 - 20.30 WELCOME COCKTAIL	18.10 - 18.50 BEST ABSTRACTS I - ORAL PRESENTATIONS	

CONGRESS INFORMATION

VENUE

Lingotto Conference Center

Via Nizza, 280

10126 Turin, Italy

Ph +39.011.6311711 - Fax +39.011.6311789

www.centrocongressilingotto.it

HOW TO REACH

The Lingotto Congress Centre is 10 minutes from the centre of Turin and the Porta Nuova train station. Connections can be made by underground buses and tram. The Lingotto train station can be reached via the Olympic footbridge.

Visitors arriving from motorways or from city by-pass will be guided directly to the Lingotto's underground car parks by road signs.

Turin's Sandro Pertini airport is 16 km from the city centre and can be reached in 80 minutes by taxi at a fixed rate.

Entrance

Pedestrian entrance: Via Nizza n. 280.

By car

- From the main motorways Piacenza, Pavia, Genova, Savona, Milano, Aosta Frejus e Pinerolo direction TORINO, continue on the South Ringroad - exit Corso Unità d'Italia then follow signs to Lingotto.
- From downtown: access to the underground parking sectors - from Via Nizza n. 230 and n. 280 bis. Underground paying car parking entrance from Via Nizza 230 or 280 bis.

Bus Routes

- From Porta Nuova railway station: Bus n. 1 or 35, get off after 12 stops. Estimated time: 20 minutes.
- From Porta Susa railway station: Bus n. 1 and get off at Via Nizza/Via Vado stop. Estimated time: 30 minutes.

Trains

- From Lingotto metro station: on foot follow Via Pannunzio, turn left in Via Passobuole then turn left again in Via Nizza. Estimated time: 20 minutes.
- From Porta Susa railway station: underground trains (www.gtt.to.it), line 1, 9 stations, terminus LINGOTTO.
- From Porta Nuova main railway station: underground trains (www.gtt.to.it), line 1, 6 stations, terminus LINGOTTO.

REGISTRATION FEES

Registration Categories	Online Registration	Onsite Registration
Standard fee *	€ 350,00	€ 400,00
Participants under 35 years	€ 250,00	€ 300,00
Nurses and Data Managers	€ 250,00	€ 300,00
Exhibitors **	€ 100,00	€ 150,00

* Sponsor staff members who have registered with a standard fee can have access to the scientific session sitting in a dedicated area.

** Exhibitor fee DOES NOT include: conference kit, participation in the scientific sessions and 3 day ticket.

Onsite registrations will be charged Euro 50,00 extra fee.

The registration fee includes:

- Participation in the scientific sessions
- Access to the exhibition and poster areas
- Conference kit
- Attendance certificate
- Lunches
- Coffee breaks
- Welcome cocktail
- 3-day ticket for urban and suburban transport (valid for 48 / 72 hours from the first validation, on urban and suburban lines as well as on subway)

REGISTRATION HOURS

Individuals and Exhibitors	
Wednesday, April 18, 2018	17.00 - 20.00
Thursday, April 19, 2018	08.00 - 18.00
Friday, April 20, 2018	07.30 - 18.00
Saturday, April 21, 2018	07.30 - 10.00
Groups	
Wednesday, April 18, 2018	13.00 - 18.00

BADGES

Badges and meeting materials can be collected at the counters in the registration area. **Remember to print the invitation letter and the badge barcode you received in the "Registration Info" automatic e-mail and to bring it with you.** All registered participants, speakers, sponsors and exhibitors will be given a badge which must be worn in order to be admitted to the scientific sessions. Badge is mandatory to enter the congress area.

A self registration system will be available in the Registration Area. Delegates, sponsors and exhibitors will be able to collect their badges simply by having their personal barcode scanned by the optical reader at the self registration machines. Speakers are kindly requested to collect their badges at the Registration desk.

The barcode on the badge stores the following personal information: name, surname, country and email address provided at the time of registration. It can be used by exhibitors to register visitors to their booths and to send additional information on their products and services.

CERTIFICATE OF ATTENDANCE

Delegates and speakers will be able to collect the certificate of attendance by having their personal barcode read at the self registration machines.

CLOAKROOM AND LUGGAGE

In the cloakroom you can leave your belongings free of charge. The cloakroom is located in the Registration Area and will be available as follows:

Thursday, April 19, 2018	08.00 - 21.00
Friday, April 20, 2018	07.30 - 19.00
Saturday, April 21, 2018	07.30 - 15.00

TURIN INFORMATION DESK

For all information about the city (guided tours, museums, public transportation, etc.), please visit the Turin Information Desk. The desk is located at the entrance and it will be available as follows:

Thursday, April 19, 2018	13.00 - 17.00
Friday, April 20, 2018	10.00 - 18.00

CATERING

Lunches, coffee breaks and the welcome cocktail are included in the registration fee. You will be admitted showing your badges. The EMN Welcome Cocktail is scheduled on Thursday, April 19, 2018 from 19.40 to 20.30 in the Catering Area. The bar is located near the Exhibition Area and it will be open as follows:

Wednesday, April 18, 2018	08.00 - 20.00
Thursday, April 19, 2018	10.00 - 19.00
Friday, April 20, 2018	08.00 - 19.00
Saturday, April 21, 2018	08.00 - 18.00

Direct payment in Euro.

AUDIO - VIDEO RECORDING

Audio-video recording is prohibited. Only authorized staff can provide audio-video recording services.

INTERNET ACCESS

WiFi is available inside the Congress Area as follows:
Network: **EMN2018**
An internet point will be available in the Exhibition area (see floor plan).

EXHIBITION AREA

Access to the exhibition area will be as follows:

Thursday, April 19, 2018	11.00 - 20.30
Friday, April 20, 2018	08.00 - 19.00
Saturday, April 21, 2018	08.00 - 14.00

FLOOR PLAN



SCIENTIFIC INFORMATION

LANGUAGE

Official language of the meeting is English. No simultaneous translation available.

ITALIAN CME CREDITS

An Italian CME application has been submitted as follows:

Main program (April 19-20-21, 2018):

- Provider Studio ER Congressi SRL: ID 828-213607.
- **No. 3,6 CME credits for Physicians** (Clinical Biochemistry, Cardiac Surgery, Cardiology, General Surgery, Palliative Care, Haematology, Epidemiology, Pharmacology and Clinical Toxicology, Medical Genetics, Geriatrics, Laboratory of Medical Genetics, General Medicine Internal Medicine, Nuclear Medicine, Microbiology and Virology, Oncology, Clinica Pathology, Radiotherapy), **Biologists, Medical Laboratory Scientists, Nurses and Chemists.**
- Educational objective: "linee guida-protocolli-procedure".
- Meet the expert sessions and sponsored symposia are not included in the submission.

In order to claim for credits attendees should:

- wear a magnetic tag in order to register their presence inside the Plenary Hall. Please ask for it at the CME Registration Desk;
- complete the CME forms. Please ask for it at the CME Registration Desk;
- attend at least 90% of the submitted program;
- return the forms at the end of the meeting to the CME Registration Desk.

EBAH CME CREDITS

The program of the "1st European Myeloma Network Meeting" has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for **no. 14 CME credits** for Physicians, Biologists, Medical Laboratory Scientists, Nurses and Chemists. EBAH Credit Points will be awarded for the Plenary Sessions and Meet the Experts Sessions.

To request credits, please fill out the form and return it to the registration desk at the end of the meeting.

We remind you that it is necessary to have an EBAH-CME account in order to claim for credits. Attendees can create an EBAH-CME account registering on the website: <http://ebah.org>.

VOTING FLAGS

Green/red flags voting for the Debate sessions to be collected inside the Plenary Hall.

POSTER AREA

Posters will be on display in the Poster Area for three days.

Posters should be installed/removed during the indicated set-up time:

Installation	Thursday, April 19, 2018	11.00 - 12.45
Tear off	Saturday, April 21, 2018	11.30- 13.45

Materials to hang posters with will be available at the poster area. The Congress provides one board for each poster, the author is responsible for hanging and for removing the poster. Please note that the organisers do not take any responsibility for returning uncollected material to the authors.

SLIDE CENTER AND SPEAKERS/CHAIRMEN RESERVED AREA

Opening hours:

Thursday, April 19, 2018	08.00 - 19.00
Friday, April 20, 2018	07.00 - 19.00
Saturday, April 21, 2018	07.00 - 13.00

MEET THE EXPERT SESSIONS

There will be six Meet the Expert Sessions on April 20 and April 21, 2018 from 8.00 to 9.00.
The registration is **Euro 10,00** per day (VAT included).
Each session is restricted to 25 participants.
Preregistration for these sessions is necessary. If still available, tickets can also be purchased during registration hours at the Registration Desk.

ROOM	FRIDAY, APRIL 20, 2018	SATURDAY, APRIL 21, 2018
LISBONA ROOM	MGUS and SMM N. Giuliani, M.V. Mateos	Start of therapy in RRMM P. Moreau, A. Waage
ATENE ROOM	MRD in clinical practice H. Avet-Loiseau, D. Hofste op Bruinink	Risk adapted therapy in NDMM elderly I.S. Nijhof, M.T. Petrucci
DUBLINO ROOM	Transplant strategies G. Jackson, C. Straka	Special conditions M. Offidani, L. Rosiñol
COPENAGHEN ROOM	Risk adapted therapy in NDMM young V. Montefusco, P. Sonneveld	Imaging: when and in which patients J. Hillengass, R. Zambello
PARIGI ROOM	How to incorporate new agents C. Driessen, S. Zweegman	Nurse: management of multiple myeloma patients from a nurse's perspective A. Bernardini, P.W.C. Bosman
ROMA ROOM	Data manager: how to deal with data management issues S.J. Lonergan, R. Troia	Biology of multiple myeloma R. Hájek, M.F. Kaiser

EMN APP

A special mobile app has been developed for this congress.
Use the app to find sessions of interest, create your own program, find and read all the abstracts.
Download the “**EMN2018**” app from Apple App store or Google-Play.

OFFICIAL WEBSITE

www.emn2018.com

PROGRAM

THURSDAY, APRIL 19, 2018

11.30-11.40 **OPENING CEREMONY** AUDITORIUM AGNELLI

11.40-11.55 **OPENING LECTURE**   AUDITORIUM AGNELLI
Myeloma from past to present - R.A. Kyle

11.55-12.45 **MGUS AND SMM: RECOMMENDATIONS AND CHALLENGES**   AUDITORIUM AGNELLI
Chairmen: R.A. Kyle, M.V. Mateos

MGUS and SMM - S. Kristinsson
M protein related disease - J. Bladé
What kind of trials do we need in the future to address open issues in SMM? - M.V. Mateos
Panel discussion

12.45-13.45 **LUNCH and POSTER VIEWING**

13.45-15.15 **CELGENE SPONSORED SYMPOSIUM** AUDITORIUM AGNELLI
IMiD® compound-based treatments for multiple myeloma
Chairman: M.V. Mateos

Welcome and introduction - M.V. Mateos
Optimizing IMiD® compounds in multiple myeloma - M.V. Mateos
Practical implications of IMiD® compound therapy - F. Gay
New targets and synergy of IMiD® compound combinations - N. van de Donk
Discussion and Q&A

15.15-16.00 **MULTIPLE MYELOMA BIOLOGY AND GENOMICS**   AUDITORIUM AGNELLI
Chairmen: N.C. Munshi, P. Sonneveld

Biology of multiple myeloma - M.S. Raab
DEBATE: CAN GENETIC ABNORMALITIES BE TARGETED?
• Applicable approach? YES - M.F. Kaiser
• Applicable approach? NO - P. Sonneveld

Panel discussion

16.00-16.30 **COFFEE BREAK and POSTER VIEWING**

16.30-18.00 **AMGEN SPONSORED SYMPOSIUM** AUDITORIUM AGNELLI
Multiple myeloma - Treatment strategies in a radically changing therapy landscape
Chairman: M. Cavo

Welcome and introduction - M. Cavo
Shaping a future for frontline treatment - A. Larocca
Myeloma relapse: deepening responses and extending survival - A. Oriol
Discussion and closing - M. Cavo

18.00-19.00 **MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA**   AUDITORIUM AGNELLI
Chairmen: B.G.M. Durie, J. Hillengass

MRD techniques - H. Avet-Loiseau
Imaging techniques - E. Zamagni

RECOMMENDATIONS AND CHALLENGES:

- How to use MRD in clinical practice - R. Owen
- What kind of trials do we need in the future to address open issues with MRD? - M. Attal

Panel discussion

19.00-19.40 **AGGRESSIVE DISEASE - EXTRAMEDULLARY DISEASE / PLASMA CELL LEUKEMIA**   AUDITORIUM AGNELLI
Chairmen: H.E. Johnsen, T. Plesner

Biology of aggressive disease - N.C. Munshi
Extramedullary disease - L. Rosiñol
Plasma cell leukemia - P. Musto

Panel discussion

19.40-20.30 **WELCOME COCKTAIL**

FRIDAY, APRIL 20, 2018

8.00-9.00 **MEET THE EXPERTS** *Simultaneous sessions in six rooms*

- MGUS and SMM
N. Giuliani, M.V. Mateos LISBONA ROOM
- MRD in clinical practice
H. Avet-Loiseau, D. Hofste op Bruinink ATENE ROOM
- Transplant strategies
G. Jackson, C. Straka DUBLINO ROOM
- Risk adapted therapy in NDMM young
V. Montefusco, P. Sonneveld COPENAGHEN ROOM
- How to incorporate new agents
C. Driessen, S. Zweegman PARIGI ROOM
- Data manager: how to deal with data management issues
S.J. Lonergan, R. Troia ROMA ROOM

9.00-10.15 **TREATMENT STRATEGY IN MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS** AUDITORIUM AGNELLI

Chairmen: H. Einsele, C. Straka

Treatment strategy: optimal induction and autologous stem cell transplantation - **M. Cavo**

Transplant strategies: elderly and allo - **M. Mohty**

Post transplantation strategies - **P.L. McCarthy**

Geriatric assessment in the elderly - **A. Larocca**

Treatment strategy in the elderly - **S. Zweegman**

Panel discussion

10.15-11.10 **RECOMMENDATIONS AND CHALLENGES: HOW TO MAKE SENSE OF THE MANY TREATMENT OPTIONS AVAILABLE AT DIAGNOSIS** AUDITORIUM AGNELLI

Chairmen: H. Goldschmidt, P.L. McCarthy

DEBATE: RISK ADAPTED THERAPY

- Are we ready? YES - **M.A. Dimopoulos**
 - Are we ready? NO - **G.J. Morgan**
- Cost/efficacy considerations - **M. Engelhardt**
What kind of trials do we need in the future to address open issues in NDMM? - **G. Cook**

Panel discussion

11.10-11.30 COFFEE BREAK and POSTER VIEWING

11.30-13.00 **JANSSEN SPONSORED SYMPOSIUM Multiple myeloma: what are your goals for treating patients in 2018?** AUDITORIUM AGNELLI

Chairmen: M. Cavo, M.V. Mateos

Welcome and introduction - **M. Cavo**

Can we cure multiple myeloma? - **N. van de Donk**

What's on the near horizon for front-line treatment? - **M.V. Mateos**

Optimizing outcomes: the changing treatment landscape in relapsed and refractory MM - **P. Moreau**

Practical management considerations for the new therapeutic options in relapsed and refractory MM - **F. Gay**

Panel discussion

Summary and close - **M. Cavo**

13.00-13.30 **PATIENT PERSPECTIVE: PATIENT ASSOCIATION TALKS** AUDITORIUM AGNELLI

Chairman: B.G.M. Durie

IMF - International Myeloma Foundation - **B.G.M. Durie**

MPE - Myeloma Patients Europe - **K. Morgan**

AIL - Italian Association against leukemia-lymphoma and myeloma - **F.N. Bombaci**

13.30-14.30 LUNCH and POSTER VIEWING

14.30-16.00 **PRIME ONCOLOGY SPONSORED SYMPOSIUM** AUDITORIUM AGNELLI

supported by BRISTOL-MYERS SQUIBB
Treatment decisions for relapsed/refractory multiple myeloma:
Fitting the pieces together

Chairman: P. Sonneveld

Welcome and introduction - P. Sonneveld

Pop quiz on relapsed/refractory multiple myeloma (R/R MM) - P. Sonneveld

Hot topic in MM: The evolving role for immunotherapy in patients

with R/R disease - G.J. Morgan

Questions from the audience

Weighing the options at first relapse - H. Einsele

Questions from the audience

How do I choose? Treatment decisions after multiple lines of therapy - M.A. Dimopoulos

Questions from the audience

Burning questions and future directions in R/R MM:

A panel discussion with the experts - P. Sonneveld

Post-activity quiz and prIME Points™ - P. Sonneveld

Adjourn

16.00-16.50 **SPECIAL CONDITIONS - WALDENSTRÖM MACROGLOBULINEMIA** AUDITORIUM AGNELLI

Chairmen: X. Leleu, S.P. Treon



AUDITORIUM AGNELLI

Diagnostic and prognostic challenges in WM - S.P. Treon

Novel targeted treatment options for WM: new challenges - E. Kastritis

Management of IgM related disorders - M.J. Kersten

Panel discussion

16.50-17.20 **COFFEE BREAK and POSTER VIEWING**

17.20-18.10 **SPECIAL CONDITIONS - AL AMYLOIDOSIS** AUDITORIUM AGNELLI

Chairmen: J. Bladé, G. Merlini



Mechanisms of disease and biomarkers - G. Merlini

Diagnosis, risk stratification and response assessment - M. Minnema

Established and novel therapies - G. Palladini

Panel discussion

18.10-18.50 **BEST ABSTRACTS I - ORAL PRESENTATIONS** AUDITORIUM AGNELLI

Chairmen: R. Hájek, F. Malavasi



BA1

SLAMF7 CAR-T CELLS WITH ENHANCED ANTI-MYELOMA EFFICACY

S. Prommersberger, S. Danhof, H. Einsele, M. Hudecek (Würzburg-DE)

BA2

NOVEL KINASE INHIBITORS AFURESERTIB AND PIM447 ARE ACTIVE ALONE AND IN COMBINATION WITH STANDARD THERAPIES, RESPECTIVELY, IN A PREDICTIVE MM IN VIVO MODEL, AND A CRISPR GENOME-WIDE SCREENING APPROACH IDENTIFIES CLINICALLY-RELEVANT BIOMARKERS DETERMINING SUSCEPTIBILITY TO THESE THERAPEUTIC STRATEGIES

N. Keane, A. Naton, M. Sharik, M. Chesi, PL Bergsagel, ME O'Dwyer (Galway-IT)

BA3

ARGININE DEPRIVATION SUSTAINS PLASMA CELL FITNESS AND BIOENERGETICS IN MULTIPLE MYELOMA

A. Romano, L. Oliva, N.L. Parrinello, J. Manteiga, K. Todoerti, L. Canziani, M. Trudu, U. Orfanelli, P. La Cava, D. Tibullo, C. Giallongo, C. Conticello, M. Marcatti, F. Ciceri, G. Tonon, A. Neri, S. Cenci, F. Di Raimondo (Catania, Milan-IT)

BA4

ENHANCED CYTOTOXICITY OF MULTIPLE MYELOMA CELLS USING DARATUMUMAB IN COMBINATION WITH NK CELLS ENGINEERED TO EXPRESS HIGH-AFFINITY CD16 (F158V)

S. Chauhan, T. Duggan, J. Daly, S. Sarkar, M. O'Dwyer (Galway-IT)

SATURDAY, APRIL 21, 2018

8.00-9.00 MEET THE EXPERTS Simultaneous sessions in six rooms

- Start of therapy in RRMM
P. Moreau, A. Waage LISBONA ROOM
- Risk adapted therapy in NDMM elderly
I.S. Nijhof, M.T. Petrucci ATENE ROOM
- Special conditions
M. Offidani, L. Rosiñol DUBLINO ROOM
- Imaging: when and in which patients
J. Hillengass, R. Zambello COPENAGHEN ROOM
- Nurse: management of multiple myeloma patients from a nurse's perspective
A. Bernardini, P.W.C. Bosman PARIGI ROOM
- Biology of multiple myeloma
R. Hájek, M.F. Kaiser ROMA ROOM

9.00-10.15 TREATMENT STRATEGY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: NOVEL THERAPIES, WHEN AND IN WHICH PATIENTS? AUDITORIUM AGNELLI Chairmen: C. Driessen, S. Lonial

- When to use novel proteasome inhibitors and immunomodulatory drugs - **F. Gay**
- When to use other classes of drugs: HDACs, nuclear pore inhibitors, proteomics - **E.M. Ocio**
- When to use monoclonal antibodies - **N. van de Donk**
- When do we choose checkpoint inhibitors - **P. Rodriguez Otero**
- Which will be the best place for bispecific antibodies and novel cellular therapies - **H. Einsele**
- Panel discussion

10.15-10.55 BEST ABSTRACTS II - ORAL PRESENTATIONS AUDITORIUM AGNELLI Chairmen: H. Goldschmidt, E. Terpos

BA5
MAGNETIC RESONANCE IMAGING BEFORE AND AFTER UPFRONT AUTOLOGOUS TRANSPLANTATION IDENTIFIES PATIENTS WITH ADVERSE OUTCOME BUT RESPONSE TO TREATMENT WITHIN THE PROSPECTIVE GMMG MM5 PHASE III TRIAL
M. Merz, T. Hielscher, A. Seckinger, A. Jauch, E.K. Mai, U. Bertsch, M.S. Raab, K. Neben, H. Salwender, I.W. Blau, H.W. Lindemann, J. Dürig, C. Scheid, M. Haenel, K. Weisel, S. Delorme, H.U. Kauczor, D. Hose, H. Goldschmidt and J. Hillengass (Heideberg, Hamburg, Berlin, Hagen, Essen, Cologne, Chemnitz, Tuebingen-DE)

BA6
MINIMAL RESIDUAL DISEASE (MRD) FOLLOW UP OF MM PATIENTS OBTAINING STRINGENT COMPLETE REMISSION (SCR) IN THE NMSG/EMN02 CLINICAL TRIAL – DEFINING SCR NUMBERS AND PREDICTION OF DISEASE PROGRESSION BY MULTIPARAMETRIC FLOW CYTOMETRY (MFC)
H.E. Johnsen, A. Schmitz, J. Støve-Bødker, P. Sonneveld, D. Hofste op Bruinink, B. van der Holt, V.H.J. van der Velden, N. Abildgaard, L. Ahlberg, N. Andersen, B. Andreasson, L. Brandefors, H.B. Christiansen, S. Faxoe, C. Fransson, M. Friestad, H. Gregersen, Y. Hammerlund, M. Hansson, E. Haukaas, M. Hector, C. Helleberg, M. Holst, A.K. Jönsson, V. Karlsson, A. Klostergaard, S. Kjær, B. Lauri, S. Lenhoff, I. Lonn, E. Myhr, B.H. Pedersen, R. Renna, T.V. Sjøgren, A. Svirskaitė, D.L. Szatkowski, S. Vangsted, A. Waage, F.H. Schjesvold, U.H. Mellqvist, H. Høholt, L.H. Madsen, H.S Christensen, R. Froberg Brøndum, M. Bøgsted, K. Dybkær (Aalborg-DK, Rotterdam-NL)

BA7
PRELIMINARY DATA OF THE ONGOING OPEN-LABEL, SINGLE-ARM PHASE II STUDY OF MP0250 IN COMBINATION WITH BORTEZOMIB + DEXAMETHASONE IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
H. Goldschmidt, M.S. Raab, J. Duerig, M. Szarejko, A. Urczyszyn, N. Grzasko, A. Vacca, S. Bringhen, M. D'Agostino, B. Gamberi, J. Haunschild, F. Hermann, U. Fiedler, K. Dawson, A. Harstrick, J. Acosta, M. Schreder, S. Knop (Heidelberg, Essen, Würzburg-DE, Gdansk, Krakow, Lublin-PL, Bari, Turin, Reggio Emilia-IT, Zürich-CH)

BA8
OUTCOME OF ELDERLY PATIENTS WITH LIGHT CHAIN AL AMYLOIDOSIS
Paolo Milani, Marco Basset, Mario Nuvolone, Roberta Mussinelli, Stefano Perlini, Andrea Foli, Giovanni Palladini, Giampaolo Merlini (Pavia - IT)

10.55-11.30 COFFEE BREAK and POSTER VIEWING

11.30-12.50 **RECOMMENDATIONS AND CHALLENGES:**   AUDITORIUM AGNELLI

**HOW TO MAKE SENSE OF THE MANY
TREATMENT OPTIONS AVAILABLE AT RELAPSE**

Chairmen: M.A Dimopoulos, G. Jackson

DEBATE: START OF THERAPY

- Biological or clinical relapse? Biological - **M. Boccadoro**
- Biological or clinical relapse? Clinical - **S. Lonial**

How to use newest combinations: is there an optimal sequencing? - **X. Leleu**

Cost/efficacy considerations - **J.L. Harousseau**

What kind of trials do we need in the future to address open issues in
RRMM? - **P. Moreau**

Panel discussion

12.50-13.30 **SIDE EFFECTS MANAGEMENT**   AUDITORIUM AGNELLI

Chairmen: H. Ludwig, A. Waage

How I treat bone disease - **E. Terpos**

How I treat cardiovascular toxicity - **S. Bringhen**

How I treat infections - **M. Delforge**

How I treat renal failure - **H. Ludwig**

Panel discussion

13.30-13.40 **CONCLUSIONS AND FINAL GREETINGS**   AUDITORIUM AGNELLI

13.40-14.30 **LIGHT LUNCH**

POSTER

POSTER

1. BIOLOGY AND PRECLINICAL

P01

GENOTYPING OF PLASMA CELL DISEASE ON THE LIQUID BIOPSY

Manzoni M., Gerber B., Spina V., Brusca A., Lionetti M., Fabris S., Barbieri M., Ciceri G., Pompa A., Forestieri G., Lerch E., Servida P., Bertoni F., Zucca E., Ghielmini M., Cortelezzi A., Cavalli F., Stussi G., Baldini L., Neri A., Rossi D. (Milan-IT, Bellinzona-CH)

P02

MAJOR CHANGES IN LEVELS OF REGULATORY CYTOKINES AND FUNCTIONAL ANTIBODIES CONTRIBUTE TO SEVERE IMMUNODEFICIENCY OF MYELOMA PATIENTS AND PERSIST AT ONE YEAR POST DIAGNOSIS

Chicca I.J., Heaney J.L.J., Iqbal G., Bowcock S., Planche T., Wood J., Raynes K., Hawkey P., Pratt G., Yong K., Dunn J.A., Drayson M.T. (Birmingham, Coventry, London-UK)

P03

A COMPENDIUM OF LONG NON-CODING RNAs TRANSCRIPTIONAL FINGERPRINT IN MULTIPLE MYELOMA

Taiana E., Ronchetti D., Agnelli L., Todoerti K., Manzoni M., Vinci C., Favasuli V., Pelizzoni F., Neri A. (Milan-IT)

P04

SINGLE PLATFORM FLOW CYTOMETRIC ABSOLUTE COUNT OF CIRCULATING PLASMA CELLS IN MULTIPLE MYELOMA IS A FEASIBLE METHOD WELL ASSOCIATED TO WORST BASELINE CHARACTERISTICS AT DIAGNOSIS

Muccio V., Gilestro M., Saraci E., Spada S., Ruggeri M., Caltagirone S., Oddolo D., Musto P., Cavo M., Pavone V., Ronconi S., Vincelli D., Cafro A.M., Cellini C., Musolino C., Molica S., Bernardini A., Gay F., Boccadoro M., Omedè P. (Turin-IT)

P06

SILENCING THE INHIBITORY CHECKPOINT CD96 ENHANCES THE CYTOTOXIC POTENTIAL OF NATURAL KILLER CELLS AGAINST MULTIPLE MYELOMA

Duggan T., Chauhan S., Daly J., Sarkar S., O'Dwyer M. (Galway-IE)

P07

LOW DOSE CYCLOPHOSPHAMIDE POTENTIATES THE ANTI-MYELOMA ACTIVITY OF DARATUMUMAB THROUGH AUGMENTATION OF MACROPHAGE-INDUCED ADCP

Naicker S., Rigalou A., McEllistram C., Henderson R., Natoni A., Chiu C., Sasser K., Ryan A., O'Dwyer M. (Galway-IE, Pennsylvania-US)

P08

TARGETING SIGLEC-7: A NOVEL IMMUNOTHERAPEUTIC APPROACH TO POTENTIATE THE CYTOTOXIC FUNCTIONS OF NATURAL KILLER CELLS AGAINST MULTIPLE MYELOMA

Daly J., Sarkar S., Natoni A., Hu J., Chauhan S., Henderson R., Duggan T., McCarthy L., McEllistram C., O'Dwyer M. (Galway-IE)

P09

LONG TERM CR MULTIPLE MYELOMA PATIENTS STUDIED WITH NGF SHOW CURED OR MGUS-LIKE MINIMAL RESIDUAL DISEASE

Gozzetti A., Raspadori D., Pacelli P., Tocci D., Staderini M., Antonioli E., Sicuranza A., Bosi A., Bocchia M. (Siena, Florence-IT)

P10

KIR 3DL1-EDU, HLA GENOTYPES AND KIR HAPLOTYPE INFLUENCE CLINICAL OUTCOME OF HIGH-RISK YOUNG MULTIPLE MYELOMA PATIENTS TREATED UP-FRONT WITH NOVEL AGENTS

Leotta S., Puglisi F., Parisi M., Calafiore V., Martino E., Romano A., Conticello C., Toscano S., Sortino G., Azzaro M.P., Di Raimondo F. (Catania-IT)

P11

A NEW, NON INVASIVE TEST TO INVESTIGATE EXTRACELLULAR VESICLES AS BIOMARKER IN MULTIPLE MYELOMA

Caivano A., Laurenzana I., Trino S., De Luca L., Lamorte D., D'Auria F., La Rocca F., Villani O., Pietrantonio G., Del Vecchio L., Musto P. (Rionero in Vulture, Naples-IT)

P12

SINGLE CELL EXOMES IN AN INDEX CASE OF AMP1Q21 MULTIPLE MYELOMA REVEAL MORE DIVERSE MUTANOMES THAN THE WHOLE TUMOUR POPULATION

Sahota S.S., Tapper W., Weston-Bell N.J., Bolomsky A., Collins A.R., Zojer N., Bryant D. (Southampton-UK, Vienna-AT)

P13

A PRELIMINARY ANALYSIS OF SOMATIC EXOME MUTATIONS OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA

Zatopkova M., Stracquadanio G., Sevcikova T., Vojta P., Simicek M., Growkova K., Chyra Kufova Z., Filipova J., Jelinek T., Rihova L., Bezdekova R., Smejkalova J., Hajduch M., Minarik J., Jungova A., Maisnar V., Pour L., Kryukov F., Hajek R. (Ostrava-CZ, Colchester-UK, Olomouc, Brno, Pilsen, Hradec Kralove-CZ, Saint Petersburg-RU)

P14

FISH IN MULTIPLE MYELOMA: BENEFITS AND OBSTACLES

Denčić Fekete M., Bila J., Jeličić J., Sretenović A., Jovanović J., Peruničić-Jovanović M., Jaković L.J., Bogdanović A., Mihaljević B. (Belgrade-YU)

P15

ACCELERATED INFUSION OF DARATUMUMAB IS SAFE IN MULTIPLE MYELOMA PATIENTS

Jak M., Oostvogels R., Minnema M.C. (Utrecht-NL)

P16

MONITORING OF INTERLEUKIN-6, INTERLEUKIN-10 AND TUMOUR NECROSIS FACTOR-ALPHA, AS PROLIFERATIVE FACTORS IN MULTIPLE MYELOMA

Kovacs-Benke E. (Birsfelden-CH)

2. NEWLY DIAGNOSED MULTIPLE MYELOMA

P17

LENALIDOMIDE, ADRIAMYCIN AND DEXAMETHASONE (RAD) REGIMEN INCREASES BONE FORMATION AND REDUCES BONE RESORPTION AND ANGIOGENESIS AS INDUCTION REGIMEN FOR NEWLY DIAGNOSED MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS TRANSPLANTATION: FINAL RESULTS OF A PHASE 2 STUDY OF THE GREEK MYELOMA STUDY GROUP

Terpos E., Zagouri F., Katodritou E., Symeonidis A., Gerofotis A., Christopoulou G., Gavriatopoulou M., Christoulas D., Kourakli A., Konstantinidou P., Kastritis E., Dimopoulos M.A. (Greek Myeloma Study Group - GR)

P18

WEEKLY CYBORD-DARA IS A SAFE AND EFFECTIVE UPFRONT TREATMENT FOR NEWLY DIAGNOSED MULTIPLE MYELOMA. PRELIMINARY RESULTS OF THE EARLY-PHASE 16-BCNI-001/CTRIAL-IE (ICORG) 16-02 STUDY

McEllistrim C., Cahill M.R., Murphy P., Pharm B., Mykytiv V., Quinn J., Bray A., Walsh J., Lenihan E., Kenny T., Hirakata G., Parker I., Hernando A., O'Dwyer M. (Galway, Cork, Dublin-IE)

P19

DARATUMUMAB PLUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (D-VMP) VERSUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (VMP) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS) INELIGIBLE FOR TRANSPLANT: A PHASE 3 RANDOMIZED STUDY (ALCYONE)

Mateos M.V., Dimopoulos M.A., Cavo M., Suzuki K., Jakubowiak A., Knop S., Doyen C., Lucio P., Nagy Z., Kaplan P., Pour L., Cook M., Grosicki S., Crepaldi A., Liberati A.M., Campbell P., Shelekhova T., Yoon S.S., Iosava G., Fujisaki T., Garg M., Chiu C., Wang J., Carson R., Crist W., Deraedt W., Nguyen H., Qi M., San-Miguel J. (Salamanca-ES, Athens-GR; Bologna-IT, Tokyo-JP, Chicago, Illinois-US, Würzburg-DE, Yvoir-BE, Lisbon-PT, Budapest-HU, Dnepropetrovsk-UA, Brno-CZ, Birmingham-UK, Katowice-PL, Cuiaba-BR, Terni-IT, Geelong-AU, Saratov-RU, Seoul-KR, Tbilisi-GE, Matsuyama-JP, Leicester-UK, Spring House, Raritan-US, Beerse-BE, Pamplona-ES)

P20

ANALYSIS OF THE PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN ELDERLY PATIENTS (65 YEARS OLD) WITH MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION

Cejalvo M.J., Rubio L., Romero S., Legarda M., Jiménez M., Perla A., Jarque I., Ribas P., Arnao M., Andreu R., Domínguez E., De la Rubia J. (Valencia-ES)

P21

ANALYSIS OF B LYMPHOCYTE SUBSETS IN MULTIPLE MYELOMA PATIENTS ACCORDING TO EUROCLASS TRIAL

Barilà G., Cinetto F., Liço A., Checuz L., Leoncin M., Trimarco V., Carraro S., Facco M., Semenzato G., Zambello R. (Padua-IT)

P22

COMPARISON OF TWO MOBILIZATION REGIMENS FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

Mariggio E., Lombardi L., Vozella F., Fazio F., Picocchi A., Foà R., Petrucci M.T. (Rome-IT)

P23

EFFECT OF NOVEL AGENTS ON THE CLINICAL OUTCOMES AND THE RISK OF EARLY DEATH OF NEWLY DIAGNOSED SYMPTOMATIC MULTIPLE MYELOMA: A SINGLE CENTRE RETROSPECTIVE ANALYSIS

Galli M., Paris L., Pavoni C., Delaini F., Rambaldi A. (Bergamo, Milan-IT)

P24

CYTOGENETIC HETEROGENEITY OF HYPERDIPLOID MULTIPLE MYELOMA IMPACTS PATIENT'S OVERALL SURVIVAL

Barilà G., Bonaldi L., Liço A., Martines A., Macrì N., Nalio S., Leoncin M., Checuz L., Carrino M., Canovas Nunes S., Manni S., Piazza F., Semenzato G., Zambello R. (Padua -IT)

P25

SMOLDERING MYELOMA APPROACH BASED ON RISK ADAPTED THERAPEUTIC STRATEGY. REPORT OF A RETROSPECTIVE REAL-LIFE STUDY PRE AND POST IMWG UPDATE

Torti L., Morelli A., Bacci F., Di Bartolomeo P. (Pescara, Bologna-IT)

P26

COMPARISON OF RADIODIAGNOSTIC METHODS (CONVENTIONAL RADIOGRAPHY, LOW-DOSE COMPUTED TOMOGRAPHY AND MAGNETIC RESONANCE IMAGING) WITH SELECTED MARKERS OF BONE METABOLISM AND BONE MARROW MICROENVIRONMENT

Krhovska P., Hermanova Z., Hrbek J., Herman M., Petrova P., Zapletalova J., Pika T., Bacovsky J., Minarik J. (Olomouc-CZ)

P27

RESULTS OF TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER INCORPORATING BORTEZOMIB SUBCUTANEOUS IN CLINICAL PRACTICE. EXPERIENCE OF ONE CENTER

García-Guiñón A., Seres Y., Marco V., Luaña A., Iserte L., Rivero E., García-Cerecedo T. (Lleida-ES)

P28

A RARE CASE OF IgM-MULTIPLE MYELOMA

Rizzi R., Mestice A., Ingravallo G., Ranieri P., Vitucci A., Mallano S., Urbano M., Albano F., Curci P., Specchia G. (Bari-IT)

P29

THALIDOMIDE'S DOSING WITHIN VTD INDUCTION SCHEME DOES NOT INFLUENCE IN THE PRETRANSPLANT EFFICACY IN PATIENTS WITH NEW DIAGNOSIS OF MULTIPLE MYELOMA

Cabrera Ruiz F.J., González Fernández A., Moreno Carrasco G., Revellas Peñas M., García Fortes M., Ruiz Arredondo J.J., García Sánchez R. (Málaga-ES)

P30

PATIENTS WITH MULTIPLE MYELOMA NOT CANDIDATES FOR TRANSPLANTATION: REAL WORLD DATA

Sánchez-Raga J.M., Pérez-Montaña A., Beltrán N., Ros T., Toledo N., Sampol A. (Palma-ES)

P31

BORTEZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE AS INDUCTION THERAPY FOR TRASPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS IN A SPANISH CENTRE

Solé M., Zapata R., Palma A., Ruiz M.A., Gil E., Rodríguez J.N., Domínguez J.F., Gómez K., Ramírez S. (Huelva-ES)

P32

VTD EXPERIENCE AS AN INDUCTION TREATMENT TO TRANSPLANT IN PATIENTS WITH NEW DIAGNOSIS OF MULTIPLE MYELOMA

González Fernández A., Cabrera Ruiz F.J., Revelles Peñas M., García Fortes M., Ruiz Arredondo J.J., Heiniger Mazo A.I., García Sánchez R. (Málaga-ES)

P33

AUTOLOGOUS STEM CELL TRANSPLANT IN MULTIPLE MYELOMA IN THE ERA OF CONVENTIONAL CHEMOTHERAPY AND NOVEL DRUGS – A SINGLE CENTRE EXPERIENCE

Minarik J., Faber E., Raida L., Szotkowski T., Skoumalová I., Pika T., Krhovská P., Bacovsky J., Zapletalova J., Scudla V., Papajik T. (Olomouc-CZ)

P34

TRANSPLANT-INELIGIBLE PATIENTS TREATED FIRST LINE WITH LENALIDOMIDE AND DEXAMETHASONE. EXPERIENCE IN ONE CENTER

Pérez-Montaña A., Sánchez-Raga J.M., Beltran N., Ros T., Sampol A. (Palma de Mallorca-ES)

P35

THE ASSOCIATION OF GLOBULIN LEVELS WITH TREATMENT RESPONSE AND SURVIVAL IN MULTIPLE MYELOMA PATIENTS

Dogu M.H., Eren R., Özdemir O., Aslan C., Altındal S., Yoku O., Suyanı E. (Istanbul-TR)

3. RELAPSED/REFRACTORY MULTIPLE MYELOMA

P36

TARGETING B-CELL MATURATION ANTIGEN (BCMA) WITH GSK2857916 ANTIBODY-DRUG CONJUGATE PROVIDES DURABLE RESPONSES IN PATIENTS (PTS) WITH HEAVILY-PRETTREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM STUDY BMA117159

Popat R., Trudel S., Lendvai N., Voorhees P., Reeves B., Libby E., Richardson P., Anderson L. Jr., Sutherland H., Yong K., Hoos A., Gorczyca M., Lahiri S., He Z., Jewell R., Opalinska J., Cohen A. (London-UK, Toronto, Vancouver-CA, New York, Charlotte, Chapel Hill, Seattle, Boston, Dallas, Philadelphia-US)

P37

UPDATED EFFICACY AND SAFETY ANALYSIS OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (DVd) VERSUS BORTEZOMIB AND DEXAMETHASONE (Vd) FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM; CASTOR)

Mateos M.V., Spencer A., Hungria V., Nooka A.K., Estell J., Barreto W., Corradini P., Min C.K., Medvedova E., Thiyagarajah P., Deraedt W., Chiu C., Schechter J.M., Weisel K. (Salamanca-ES, Melbourne-AU, São Paulo-BR, Atlanta-US, Concord-AU, Milan-IT, Seoul-KR, Portland-US, High Wycombe-UK, Beerse-BE, Spring House, Raritan-US, Tuebingen-DE)

P38

UPDATED EFFICACY AND SAFETY ANALYSIS OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRd) VERSUS LENALIDOMIDE AND DEXAMETHASONE (Rd) FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM; POLLUX)

Moreau P., White D., Benboubker L., Cook G., Leiba M., Morton J., Joy Ho P., Kim K., Takezako N., Trivedi S., Wu K., Casneuf T., Chiu C., Schechter J., Dimopoulos M.A. (Nantes-FR, Halifax-CA, Tours-FR, Leeds-UK, Ramat Gan-IL, South Brisbane, Camperdown-AU, Seoul-KR, Tachikawa-JP, Spring House-US, Beerse-BE, Raritan-US, Athens-GR)

P39

FIRST REPORT ON OS AND IMPROVED PFS IN A COMPLETED PHASE 2 STUDY (O-12-M1) OF MELFLUFEN IN ADVANCED RRMM

Bringhen S., Paba-Prada C., Voorhees P., Plesner T., Sonneveld P., Mellqvist U. H., Zonder J., Reeves B., Palumbo A., Byrne C., Harmenberg J., Nordström E., Zubair H., Lindberg J., Richardson P. G. (Turin-IT, Boston, Charlotte-US, Vejle-DK, Rotterdam-UK, Borås-SE, Detroit, Chapel Hill-US, Zurich-CH, Stockholm-SE)

P40

MELFLUFEN THERAPY FOR HEAVILY PRETTREATED RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS REFRACTORY TO DARATUMUMAB AND/OR POMALIDOMIDE: EARLY EFFICACY DATA (HORIZON)

Mateos M.V., Oriol Rocafiguera A., Rodríguez Otero P., Bladé J., Larocca A., Moreau S. J., Cavo M., Mazumder A., Alegre A., Hassoun H., Maisel C., Paner A., Gabrail N., Halka K., Zonder J., Ocio E., Byrne C., Harmenberg J., Lindberg J., Nordström E., Thuresson S., Richardson G. P. (Salamanca, Badalona, Pamplona, Barcelona-ES, Turin-IT, Gainesville-US, Bologna-IT, Hawthorne-US, Madrid-ES, New York, Dallas, Chicago, Canton, Temple, Detroit-US, Stockholm-SE, Boston-US)

P41

SUBCUTANEOUS DARATUMUMAB IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE 1B STUDY (PAVO)

Mateos M.V., Chari A., Nahi H., Lokhorst H., Kaufman J.L., Moreau P., Oriol A., Plesner T., Benboubker L., Hellems P., Masterson T., Clemens P.L., Liu K., San-Miguel J., Usmani S.Z. (Salamanca-ES, New York-US, Stockholm-SE, Amsterdam-NL, Atlanta-US, Nantes-FR, Barcelona-SE, Vejle-DK, Tours-FR, Beerse-BE, Spring House, Raritan-US, Pamplona-SE, Charlotte-US)

P42

CAROTID-FEMORAL PULSE WAVE VELOCITY AND CARDIOVASCULAR EVENTS IN MULTIPLE MYELOMA PATIENTS TREATED WITH CARFILZOMIB

Bruno G., Maffei I., Iannaccone A., Crea T., Salvini A., Gay F., Bringham S., Veglio F., Milan A. (Turin-IT)

P43

EFFICACY OF RETREATMENT WITH IMMUNOMODULATORY DRUGS AND PROTEASOME INHIBITORS FOLLOWING DARATUMUMAB TREATMENT IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS

Oostvogels R., Jak M., Minnema M.C. (Utrecht-NL)

P44

FIRST SYMPTOMATIC RELAPSE/PROGRESSION OF MULTIPLE MYELOMA: A SINGLE CENTRE RETROSPECTIVE ANALYSIS OF THE DETERMINANTS OF CHOICE OF SECOND-LINE TREATMENTS

Galli M., Paris L., Pavoni C., Delaini F., Rambaldi A. (Bergamo, Milan-IT)

P45

ORAL CYCLOPHOSPHAMIDE'S ADDITION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS WITH BIOCHEMICAL PROGRESSION DURING LENALIDOMIDE-DEXAMETHASONE TREATMENT

Cesini L., Siniscalchi A., Grammatico S., Andriani A., Fiorini A., De Rosa L., Za T., Rago A., Caravita T., Petrucci M.T. (Rome, Viterbo, Latina-IT)

P46

THE OUTCOME OF SECOND AUTOLOGOUS STEM CELL TRANSPLANTATIONS IN MULTIPLE MYELOMA – A SINGLE CENTRE EXPERIENCE

Minarik J., Faber E., Raida L., Szotkowski T., Skoumalova I., Pika T., Krhovska P., Bacovsky J., Zapletalova J., Scudla V., Papajik T. (Olomouc-CZ)

P47

COMFORTABLE MANAGEMENT OF INFUSION-RELATED DURING DARATUMUMAB FIRST INFUSION

Parisi M., Del Fabro V., Martino E., Calafiore V., Sapienza G., Conticello C., Romano A., Di Raimondo F. (Catania-IT)

P48

EFFICACY, SAFETY AND TOLERABILITY OF CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE (KRD) REGIMEN IN RR/MM

Calafiore V., Martino E., Parisi M., Sapienza G., Del Fabro V., Leotta S., Romano A., Conticello C., Di Raimondo F. (Catania-IT)

P49

NORWEGIAN REAL-LIFE EXPERIENCE OF PREAPPROVAL CARFILZOMIB THROUGH COMPASSIONATE USE NAMED PATIENT PROGRAM (NPP) FOR RELAPSING/REFRACTORY MULTIPLE MYELOMA

Haarstad I., Lysén A., Schjesvold F. (Oslo-NO)

P50

KRD (CARFILZOMIB PLUS LENALIDOMIDE PLUS DEXAMETHASONE) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A REAL LIFE SURVEY IN CAMPANIA REGION IN SOUTHERN ITALY

Palmieri S., Rocco S., Migliaccio I., Cerchione C., Catalano L., Ferrara K., Peluso I., Monaco G., Farina G., Gagliardi A., Barone M., Esposito D., Amico V., Arcamone M., Fontana R., Sementa A., Sica A., Svanera G., Pane F., Ferrara F. (Naples, Caserta, Pagani, Aversa, Benevento, Salerno, Avellino, Giugliano in Campania-IT)

P51

LONG TERM DISEASE CONTROL WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A REAL LIFE EXPERIENCE

Parisi M., Conticello C., Leotta S., Martino E., Calafiore V., Del Fabro V., Piroso M.C., Romano A., Di Raimondo F. (Catania-IT)

P52

RELEVANT REDUCTION OF POMALIDOMIDE-RELATED NEUTROPENIA BY INTENSIVE USE OF MYELOID GROWTH FACTOR

Parisi M., Calafiore V., Martino E., Del Fabro V., Romano A., Sapienza G., Conticello C., Di Raimondo F. (Catania-IT)

P53

CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SINGLE CENTRE REAL-LIFE EXPERIENCE

Guidotti F., Ferla V., Gregorini A.I., Rossi F.G., Pompa A. (Milan-IT)

P54

BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REAL-LIFE EXPERIENCE

Cerchione C., Catalano L., Pareto A.E., Nappi D., Basile S., Marano L., Peluso I., Simeone L., Vitagliano O., Romano A., Palmieri S., Rocco S., Pane F., Ferrara F. (Naples-IT)

P55

IMPACT OF NOVEL AGENTS ON AGGRESSIVE RELAPSE OF MULTIPLE MYELOMA: A SINGLE CENTER EXPERIENCE

Martino E., Parisi M., Calafiore V., Sapienza G., Del Fabro V., Romano A., Conticello C., Di Raimondo F. (Catania-IT)

P56

CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: A REAL-LIFE EXPERIENCE

Cerchione C., Ferrara K., Peluso I., Di Perna M., Zacheo I., Nappi D., Pareto A. E., Pane F., Catalano L. (Naples-IT)

P57

POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF HEAVILY PRETREATED MULTIPLE MYELOMA

Cerchione C., Nappi D., Pareto A. E., Migliaccio I., Zacheo I., Di Perna M., Peluso I., Ferrara K., Pane F., Catalano L. (Naples-IT)

P58

BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REAL-LIFE EXPERIENCE

Cerchione C., Zacheo I., Di Perna M., Nappi D., Pareto A. E., Peluso I., Ferrara K., Pane F., Catalano L. (Naples-IT)

P59

IXAZOMIB, LENALIDOMIDE, AND DEXAMETHASONE FOR RELAPSED MULTIPLE MYELOMA: AN EARLY SINGLE CENTER EXPERIENCE IN RUSSIA

Luchinin A., Semochkin S., Minaeva N., Samarina S. (Kirov, Moscow-RU)

4. SPECIAL CONDITIONS

P60

A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY OF DARATUMUMAB MONOTHERAPY FOR PATIENTS (PTS) WITH INTERMEDIATE OR HIGH-RISK SMOLDERING MULTIPLE MYELOMA (SMM): CENTAURUS

Cavo M., Hofmeister C.C., Chari A., Cohen Y.C., Spencer A., Voorhees P., Estell J., Venner C., Sandhu I., Jenner M., Williams C., van de Donk N.W.C.J., Beksac M., Kuppens S., Bandekar R., Neff T., Heuck C., Qi M., Goldschmidt H., Ola Landgren C. (Bologna-IT, Columbus, New York-US, Tel Aviv-IL, Melbourne-AU, Charlotte-US, Concord-AU, Edmonton-CA, Southampton, Leicestershire-UK, Amsterdam-NL, Ankara-TR, Beerse-BE, Spring House-US, Heidelberg-DE, New York-US)

P61

SEMAPHORIN 4D CORRELATES WITH INCREASED BONE RESORPTION, HYPERCALCEMIA AND DISEASE STAGE IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA

Terpos E., Ntanasis-Stathopoulos I., Christoulas D., Bagratuni T., Bakogeorgos M., Gavriatopoulou M., Eleutherakis-Papaiaikovou E., Kanellias N., Kastritis E., Dimopoulos M.A. (Athens-GR)

P62

TWO DOSE SERIES OF HIGH-DOSE INFLUENZA VACCINE IS ASSOCIATED WITH LONGER DURATION OF SEROLOGIC IMMUNITY IN PATIENTS WITH PLASMA CELL DISORDERS

Branagan A., Duffy E., Foster C., Zhang L., Verma R., Gan G., Li F., Dhodapkar M. (Boston, New Haven-US)

P63

OUTCOME OF CYTOGENETICS IN PATIENTS WITH NEWLY DIAGNOSED EXTRAMEDULLARY MYELOMA UNDERGOING STEM-CELL TRANSPLANTATION

Gagelmann N., Eikema D.J., Koster L., Caillot D., Pioltelli P., Bargay Leonart J., Reményi P., Blaise D., Schaap N., Trneny M., Passweg J., Parody Porras R., Cahn J.Y., Musso M., Poiré X., Kobbe G., Itälä-Remes M., Pavone V., Fouillard L., Maertens J., Bron D., Pouli A., Schroyens W., Garderet L., Kröger N. (Hamburg-DE, Leiden-NL, Dijon-FR, Monza-IT, Palma de Mallorca-ES, Budapest-HU, Marseille-FR, Nijmegen-NL, Prague-CZ, Basel-CH, Barcelona-ES, Grenoble-FR, Palermo-IT, Brussels-BE, Duesseldorf-DE, Turku-FI, Tricase-IT, Meaux-FR, Leuven-BE, Athens-GR, Antwerp-BE, Paris-FR)

P64

A REAL WORLD MULTICENTER RETROSPECTIVE ANALYSIS OF EXTRAMEDULLARY DISEASE FROM BALKAN MYELOMA STUDY GROUP AND BARCELONA UNIVERSITY: COMPARISON OF PARAOSSEROUS AND SOFT TISSUE PLASMACYTOMAS

Beksac M., Kanellias N., Rosinol L., Seval G.C., Ozet G., Goranova-Marinova V., Coriu D., Bila J., Ozsan H., Balic L.I., Ivanaj A., Kastritis E., Blade J., Dimopoulos M.A. (Ankara-TR, Athens-GR, Barcelona-ES, Pulovdiv-BG, Bucharest-RO, Belgrade-YU, Izmir-TR, Sarajevo-BA, Tirana-AL)

P65

TREATMENT WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH LIGHT CHAIN AL AMYLOIDOSIS AND MULTIPLE MYELOMA

Basset M., Milani P., Folli A., Merlini G., Palladini G. (Pavia-IT)

P66

THE ROLE OF 18F-FDG PET/ CT IN NEWLY DIAGNOSED PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFIKANCE (MGUS): ONE CENTER EXPERIENCE FROM CZECH REPUBLIC

Sandeká V., Ševčíková S., Zdeňek A., Krejčí M., Štork M., Král Z., Pour L. (Brno-CZ)

P67

LOW INCIDENCE OF SKELETAL-RELATED EVENTS AT THE TIME OF FIRST RELAPSE IN PATIENTS WITH MULTIPLE MYELOMA WHO RECEIVED BORTEZOMIB-BASED REGIMENS AS FIRST LINE TREATMENT

Terpos E., Kanellias N., Mouloupoulos L.A., Christoulas D., Gavriatopoulou M., Migkou M., Fotiou D., Koureas A., Bagratuni T., Koutoulidis V., Kastritis E., Dimopoulos M.A. (Athens-GR)

P68

ALLOGRAFT IN MULTIPLE MYELOMA: EXPERIENCE OF MULTIPLE MYELOMA GIMEMA LAZIO GROUP

Vozella F., Iori A.P., Cerretti R., Severino A., Chiusolo P., Piciocchi A., Cesini L., Mariggiò E., Fazio F., Cudillo L., Franceschini L., Za T., Sica S., Petrucci M.T., De Stefano V., De Rosa L., Arcese W., Foà R. (Rome-IT)

P69

PECULIARITIES AND HETEROGENEITIES OF EXTRAMEDULLARY DISEASE OF MULTIPLE MYELOMA IN THE “NOVEL AGENTS ERA”. COMPARISON OF SOFT-TISSUE AND BONE-RELATED SHAPES IN A RETROSPECTIVE REAL-LIFE ANALYSIS

Torti L., Morelli A., Bacci F., Di Bartolomeo P. (Pescara, Bologna-IT)

P70

SAFETY AND COMFORT OF DOMESTIC BORTEZOMIB INJECTION IN REAL LIFE EXPERIENCE

Cerchione C., Nappi D., Pareto A.E., Romano A., Di Perna M., Zacheo I., Pane F., Catalano L. (Naples-IT)

P71

AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN ELDERLY PATIENTES WITH MULTIPLE MYELOMA

Solé M., Zapata R., Palma A., Ramírez S., Domínguez J.F., Rodríguez J.N., Gómez K., Gil E. (Huelva-ES)

P72

EXTRAMEDULLARY PLASMACYTOMA-LIKE POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD): A RARE COINCIDENCE OR SOMETHING MORE?

Ferla V., Guidotti F., Gregorini A.I., Rossi F.G., Pompa A. (Milan-IT)

P73

BVD IS EFFECTIVE IN RELAPSED LYMPHOPLASMACYTIC LYMPHOMA PATIENTS REFRACTORY OR INTOLLERANT TO RITUXIMAB: 2 CLINICAL CASE REPORTS

Liço A., Barilà G., Checuz L., Leoncin M., Semenzato G., Zambello R. (Padua-IT)

P74

SAFE AND EFFECTIVE TREATMENT OF MULTIPLE MYELOMA IN A PATIENT AFFECTED BY BRUGADA SYNDROME

Sapienza G., Calafiore V., Di Martino E., Parisi M., Del Fabro V., Conticello C., Romano A., Di Raimondo F. (Catania-IT)

P75

A RARE CASE OF POLYCYTHEMIA VERA AND PLASMA CELL MYELOMA IN THE SAME PATIENT

Ozatli D., Meletli Ö. (Samsun-TR)

5. NURSE

P76

PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL FIVE YEARS AFTER ORAL CRYOTHERAPY IMPLEMENTED IN HIGH-DOSED MELPHALAN CONDITIONING FOR THE PREVENTION OF ORAL MUCOSITIS

Naegele M., Leppla L., Ihorst G., Hasemann M., Rebařka A., Mößner U., Koller A., Engelhardt M. (Freiburg-DE, Vienna-AT)

ABSTRACT REVIEWERS

Annalisa

Patricia W.C.

Michel

Christoph

Nicola

Roman

Matthias

Xavier

Monique

Mohamad

Vittorio

Torben

Marc

Paula

Laura

Evangelos

Anders

Sonja

Bernardini

Bosman

Delforge

Driessen

Giuliani

Hájek

Hellberg-Naegele

Leleu

Minnema

Mohty

Montefusco

Plesner

Raab

Rodriguez Otero

Rosiñol

Terpos

Waage

Zweegman

Turin, Italy

Amsterdam, The Netherlands

Leuven, Belgium

St. Gallen, Switzerland

Parma, Italy

Ostrava, Czech Republic

Freiburg, Germany

Poitiers, France

Utrecht, The Netherlands

Paris, France

Milan, Italy

Vejle, Denmark

Heidelberg, Germany

Navarra, Spain

Barcelona, Spain

Athens, Greece

Trondheim, Norway

Amsterdam, The Netherlands

ACKNOWLEDGEMENTS

PLATINUM SPONSORS



GOLD SPONSORS



CONTRIBUTORS



**1st European
Myeloma Network
Meeting**

EMN

ORGANIZING SECRETARIAT

Studio E.R. Congressi

Via Marconi 36 - 40122 Bologna - Italy

Ph.: +39 051 4210559 - Fax: +39 051 4210174

E-mail: emn2018@ercongressi.it

www.ercongressi.it